Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Geron’s Potential Blockbuster Imetelstat Faces Unexpected AdComm In MDS

Before 2024 PDUFA Date

Executive Summary

Geron’s highly anticipated telomerase inhibitor has been given a user fee date by the US Food and Drug Administration next year and will also be subject to an advisory committee meeting, despite largely positive analyst sentiment on clinical results to date.

You may also be interested in...

UPDATED: Regeneron Wins Same-Day Veopoz, High-Dose Eylea US FDA Approvals

Veopoz (pozelimab) approval showed the FDA was reassured that Regeneron’s contract manufacturer is ready to supply high-dose Eylea, a key product for the company as competition picks up.

Geron Sees Blockbuster Opportunity For Imetelstat, Eyeing Broader Market Than Reblozyl’s

The company reported positive results from its study in lower-risk myelodysplastic syndrome, where it forecasts a market potentially exceeding 30,000 in US and major European markets and generating up to $1.2bn in sales.

Bloom Harnesses Gut-Brain Axis To Develop ‘Bugs As Drugs’ For Rare Neurological Disease


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts